Last updated: February 22, 2026
What Does the Drug NDC 63402-0204 Refer To?
NDC 63402-0204 corresponds to Adapalene Gel 0.1%. It is marketed as a topical medication predominantly used for treating acne vulgaris. The drug is distributed under the brand name Differin Gel, originally developed by Galderma. It competes within the dermatological acne treatment segment, alongside other retinoids and combination therapies.
Market Overview
Global Acne Treatment Market Size: Valued at approximately USD 4.6 billion in 2021, with a compound annual growth rate (CAGR) of 4.2% projected through 2028 (Grand View Research, 2022).
Key Drivers:
- Increasing prevalence of acne, especially among adolescents and young adults.
- Growing demand for topical and non-prescription acne medications.
- Rising awareness about skin health.
- Expanding product portfolio and patent expirations leading to generic entry.
Market Segments:
- Prescription drugs: Retinoids, antibiotics, hormonal therapies.
- Over-the-counter (OTC) products: Adapalene gels, benzoyl peroxide, salicylic acid.
Competitive Landscape:
- Major brands: Differin (Galderma), Epiduo (Epiduo Forte), Aczone (Medicis), generic formulations.
- Generics account for over 80% of units sold post-patent expiry.
Product Status and Patent Timeline
Original patent expiration:
- The original patent for Differin Gel expired in the US in 2018, opening the market to generics.
Current patent protections:
- Patents for formulation and method of use may extend into the mid-2020s in certain jurisdictions.
Regulatory approvals:
- FDA approved adapalene for OTC sale in 2016, increasing market penetration.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Retail Price (USD) |
Notes |
| 2016 |
USD 35.00 for 15g |
Post-OTC approval, initial prices high |
| 2018 |
USD 20.00 |
Generic competition introduction |
| 2020 |
USD 14.50 |
Continued price decline, increased volume |
| 2022 |
USD 12.50 |
Price stabilization as competition stabilizes |
Current Market Price (as of Q1 2023)
- Typical OTC 0.1% adapalene gel (15g tube): USD 12.50 – USD 15.00.
- Larger 45g tubes: USD 25.00 – USD 35.00 depending on retailer and formulation.
Price Projection (2023-2027)
- Short-term (2023-2024): Prices expected to stabilize around USD 12.00 – USD 13.50 as generic competition gains market share. Limited price erosion as the product remains a dominant OTC acne treatment.
- Mid-term (2025-2027): Prices could decline an additional 10-15% due to increased generic competition and potential new formulations entering the market.
- Long-term: Pricing may plateau if no new patent protections or formulations emerge. Introduction of combination therapies or novel retinoids could impact the category but are unlikely to affect existing adapalene formulations significantly.
Future Market Dynamics
Regulatory changes:
- Potential for OTC reclassification in further jurisdictions may increase accessibility, exerting downward pressure on prices.
- Patent litigations or new formulation patents could temporarily stabilize or increase prices.
Market penetration:
- Commercial expansion into emerging markets could broaden overall sales volume; however, retail prices in these regions are typically lower than in North America.
Innovation prospects:
- New delivery systems (e.g., microsphere, nano-emulsions) and combination therapies could differentiate future products but are unlikely to impact current prices within the forecast window.
Summary of Key Data
| Metric |
2022 |
2023-2024 |
2025-2027 |
| Market Value |
USD 1.1 billion (assuming OTC segment) |
Growth with volume, prices stable |
Growth with volume, slight price erosion |
| Average Price (per 15g tube) |
USD 12.50 |
USD 11.50–USD 13.00 |
USD 10.00–USD 12.00 |
| Market Share (Generics) |
>80% |
Stable |
Stable or increasing |
| CAGR |
- |
Approx. 0% to -5% |
Approx. -5% |
Key Takeaways
- The product, Adapalene Gel 0.1%, entered OTC markets early post-patent expiry.
- Prices declined steadily from initial post-approval levels but stabilized by 2022.
- The market is highly competitive, with over 80% of sales via generics.
- Future prices are likely to decline marginally, influenced by increased competition and potential new formulations.
- Market growth hinges on expanding into emerging markets and potential reformulations that could extend product lifecycle.
FAQs
Q1: How will patent expirations affect prices?
A: Patent expiries opened the market for generics, leading to significant price declines. Continued patent protections can temporarily keep prices higher.
Q2: Are there new formulations of adapalene in development?
A: No major new formulations are expected within the near term; current innovations focus on delivery systems and combination products.
Q3: What impact will OTC regulations have?
A: Reclassification can increase market access, potentially lowering retail prices and expanding volume sales.
Q4: How does competition influence pricing?
A: High generic competition drives prices downward. Limited new entrants tend to stabilize prices.
Q5: Which regions will see the highest growth?
A: Emerging markets like Asia-Pacific and Latin America will account for the fastest growth, driven by increasing acne prevalence and expanding OTC availability.
References
- Grand View Research. (2022). Acne treatment market size, share & trends analysis.
- U.S. Food & Drug Administration. (2016). OTC approval of adapalene.
- IQVIA. (2022). Pharmaceutical market analysis extract.
- Statista. (2022). Global acne medication revenue projections.
- Clinical pharmacology databases. (2022). Adapalene patent and formulation data.
[1] Grand View Research. (2022). Acne treatment market size, share & trends analysis.
[2] U.S. Food & Drug Administration. (2016). OTC approval of adapalene.
[3] IQVIA. (2022). Pharmaceutical market analysis extract.
[4] Statista. (2022). Global acne medication revenue projections.
[5] Clinical pharmacology databases. (2022). Adapted with market and patent insights.
